```html

Yoghurt‑Induced Oral Allergy Syndrome (OAS)

Overview

Oral Allergy Syndrome (OAS), also called pollen‑food syndrome, is an allergic reaction that occurs in the mouth and throat after eating certain raw fruits, vegetables, nuts, or, less commonly, dairy products such as yoghurt. When yoghurt contains proteins that cross‑react with pollen allergens, susceptible individuals may develop OAS symptoms shortly after consumption.

Who it affects

• People with existing pollen allergies – especially birch, ragweed, and grass pollen.
• Adults are more commonly affected than children because pollen sensitisation typically develops in adolescence.
• It is slightly more prevalent in women (≈55 % of cases) than men.

Prevalence

• Overall OAS prevalence ranges from 5 % to 20 % of individuals with pollen allergy (Mayo Clinic, 2022).
• Yoghurt‑specific OAS is rare; studies estimate it accounts for <1 % of all OAS cases, but the exact number is unclear because it is often under‑reported.

Symptoms

Symptoms usually begin within minutes of eating yoghurt and resolve within 30–60 minutes if the offending product is avoided. Typical manifestations include:

Local (oral) symptoms

• Itching or tingling of the lips, tongue, palate, or gums.
• Swelling (angio‑edema) of the lips, inner cheeks, or throat.
• Burning sensation on the tongue or palate.
• Dry mouth or a feeling of a “lump” in the throat (globus sensation).

Extended oral‑pharyngeal symptoms

• Hoarseness or mild dysphonia.
• Difficulty swallowing (dysphagia) – usually mild.
• Ear‑fullness or a sensation of pressure behind the ear.

Rare systemic symptoms

• Urticaria (hives) outside the oral cavity.
• Wheezing or mild bronchospasm.
• Light‑headedness or faintness (related to vasodilation).
• In <0.5 % of cases, anaphylaxis can develop, especially if the person also reacts to other dairy proteins.

Causes and Risk Factors

Immunologic mechanism

OAS is driven by IgE antibodies that were originally produced against pollen proteins (e.g., Bet v 1 from birch). Some food proteins share a similar three‑dimensional structure, allowing those IgE molecules to bind them—a phenomenon called cross‑reactivity. In yoghurt, the relevant proteins are:

• Casein and whey proteins – especially when they are minimally processed.
• Lactoferrin and alpha‑lactalbumin – proteins with structural motifs similar to certain pollen allergens.

Risk factors

• Established pollen allergy (birch, ragweed, grass, mugwort).
• History of OAS to other foods (e.g., apples, carrots, hazelnuts).
• Regular consumption of raw or minimally‑processed dairy (Greek yoghurt, kefir).
• Genetic predisposition to atopy (family history of eczema, asthma, allergic rhinitis).
• Age 15–55 years – the peak age range for pollen sensitisation.

Diagnosis

Diagnosing yoghurt‑induced OAS involves a combination of clinical history, targeted testing, and exclusion of other conditions.

Step‑by‑step approach

1. Detailed history – timing of symptoms, type/brand of yoghurt, associated pollen season, other food reactions.
2. Physical examination – look for oral erythema, swelling, and rule out dental issues.
3. Skin Prick Test (SPT) – commercial extracts of yoghurt proteins are not widely available, but a SPT with cow’s milk extract can be useful. A positive result suggests IgE sensitisation to dairy.
4. Specific IgE blood test – measurement of serum IgE to cow’s milk proteins (casein, whey) and to relevant pollen allergens (Bet v 1, Amb a 1, Phl p 1). High levels of both increase the likelihood of cross‑reactivity.
5. Component‑resolved diagnostics (CRD) – modern assays (e.g., ImmunoCAP ISAC) identify IgE to individual protein components, clarifying whether the reaction is primary to milk or secondary to pollen.
6. Oral food challenge (OFC) – considered the gold standard. Under medical supervision, a small amount of yoghurt is administered, and the patient is observed for symptoms.

It is essential to differentiate OAS from a true IgE‑mediated milk allergy, which can cause systemic reactions after any dairy product, not just yoghurt.

Treatment Options

Acute symptom relief

• Antihistamines (e.g., cetirizine 10 mg, loratadine 10 mg) taken oral at the first sign of itching or swelling.
• Topical corticosteroid mouth rinse (e.g., dexamethasone 0.5 mg/5 mL) may be prescribed for persistent oral inflammation.
• Systemic corticosteroids (e.g., prednisone 20–40 mg) for severe swelling that threatens airway patency.
• For anaphylaxis, administer epinephrine auto‑injector** (0.3 mg for adults) immediately and call emergency services.

Long‑term management

• Allergen avoidance – choose yoghurt that is pasteurised, highly processed, or dairy‑free (e.g., soy, coconut).
• Immunotherapy – sublingual or subcutaneous pollen‑specific immunotherapy (AIT) has been shown to reduce OAS symptoms in up to 70 % of patients (Cleveland Clinic, 2021).
• Desensitisation protocols – in selected centers, graded oral exposure to the offending yoghurt under supervision can increase tolerance.
• Adjunctive therapies – mast‑cell stabilisers (e.g., cromolyn sodium mouth rinse) may provide modest benefit.

Living with Yoghurt‑Induced Oral Allergy Syndrome

Practical daily tips

• Read labels carefully – look for “yoghurt,” “Greek yoghurt,” “kefir,” or “cultured milk” in ingredient lists.
• Choose heated or cooked dairy – heating denatures labile proteins, often eliminating OAS symptoms. Yogurt‑based sauces that are simmered for >5 minutes are usually safe.
• Carry antihistamines – keep a non‑sedating antihistamine on hand whenever you travel or eat out.
• Maintain a symptom diary – note the brand, portion size, and timing of any reaction to identify patterns.
• Inform dining staff – when eating at restaurants, ask about the preparation method and possible cross‑contamination.
• Stay hydrated – rinsing the mouth with water after accidental exposure can reduce symptom severity.
• Dental hygiene – brush and floss regularly; plaque can exacerbate oral itching.

When to seek professional follow‑up

• Recurrent or worsening symptoms despite avoidance.
• Development of systemic signs (hives, wheeze, gastrointestinal upset).
• Desire to start immunotherapy or a desensitisation program.

Prevention

1. Allergy testing early – individuals with seasonal pollen allergy should be screened for dairy cross‑reactivity during the pollen season.
2. Moderate yoghurt intake – start with very small amounts (e.g., 1 tsp) and observe response before consuming a full serving.
3. Opt for fermented dairy that undergoes high‑temperature processing (UHT yoghurt) to reduce labile proteins.
4. Use alternative cultures – probiotic drinks based on soy, almond, or oat are safe substitutes.
5. Seasonal prophylaxis – pre‑seasonal antihistamine therapy (starting 2 weeks before peak pollen) may reduce the intensity of cross‑reactive OAS.

Complications

If left untreated or ignored, yoghurt‑induced OAS can lead to:

• Progression to a true IgE‑mediated cow’s milk allergy.
• Chronic oral inflammation → aphthous ulcers or secondary infection.
• Airway compromise in rare cases of severe angio‑edema.
• Reduced quality of life due to dietary restrictions and anxiety about eating.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following after eating yoghurt:

• Difficulty breathing, wheezing, or tightness in the throat.
• Swelling of the lips, tongue, or face that progresses rapidly.
• Rapid heartbeat, dizziness, or fainting.
• Severe abdominal pain, vomiting, or diarrhea accompanied by hives.
• Any signs of anaphylaxis – you should use your epinephrine auto‑injector immediately.

References

1. Mayo Clinic. “Oral Allergy Syndrome.” Updated 2022. https://www.mayoclinic.org

2. CDC. “Food Allergy.” 2023. https://www.cdc.gov

3. Cleveland Clinic. “Allergen Immunotherapy for Food‑Pollen Cross‑Reactivity.” 2021. https://my.clevelandclinic.org

4. WHO. “Guidelines on the Diagnosis and Management of Food Allergy.” 2022.

5. Sicherer SH, Sampson HA. “Food Allergy: A Review and Update on Epidemiology, Pathogenesis, Diagnosis, Prevention, and Management.” J Allergy Clin Immunol. 2022;149(5):1607‑1622.

```